
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5705808/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Room for improvement in capturing cancer family history in a gynecologic oncology outpatient setting. Gynecologic Oncology Reports, 2022, 40, 100941.	0.6	2
2	Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer. Cancer Discovery, 2022, 12, 1904-1921.	9.4	25
3	The National Deficit of Black and Hispanic Physicians in the US and Projected Estimates of Time to Correction. JAMA Network Open, 2022, 5, e2215485.	5.9	23
4	Relative disclosure of information on hereditary cancer syndromes: A systematic review and meta-analysis Journal of Clinical Oncology, 2022, 40, 10592-10592.	1.6	0
5	Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis Journal of Clinical Oncology, 2022, 40, e17597-e17597.	1.6	0
6	A Perspective on James Marion Sims, MD, and Antiblack Racism in Obstetrics and Gynecology. Journal of Minimally Invasive Gynecology, 2021, 28, 153-155.	0.6	14
7	Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic. Gynecologic Oncology, 2021, 160, 492-498.	1.4	24
8	Financial toxicity, mental health, and gynecologic cancer treatment: The effect of the COVIDâ€19 pandemic among lowâ€income women in New York City. Cancer, 2021, 127, 2399-2408.	4.1	27
9	Leveraging Health Information Technology to Collect Family Cancer History: A Systematic Review and Meta-Analysis. JCO Clinical Cancer Informatics, 2021, 5, 775-788.	2.1	4
10	Mental Health of US Medical Students During the COVID-19 Pandemic. Journal of General Internal Medicine, 2021, 36, 3295-3297.	2.6	26
11	Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecologic Oncology, 2021, 162, 506-516.	1.4	39
12	Validation of a Circulating Tumor <scp>DNA</scp> -Based <scp>Next-Generation</scp> Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Oncologist, 2021, 26, e1971-e1981.	3.7	11
13	Inferior Mesenteric Arterial Supply to a Symptomatic Uterine Myoma. Journal of Minimally Invasive Gynecology, 2020, 27, 248-249.	0.6	0
14	Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature. International Journal of Gynecological Cancer, 2020, 30, 1372-1377.	2.5	20
15	Outcomes of minimally invasive surgery for patients with endometrial carcinoma involving the cervix. International Journal of Gynecological Cancer, 2020, 30, 619-625.	2.5	6
16	Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer. American Journal of Obstetrics and Gynecology, 2020, 223, 725.e1-725.e9.	1.3	87
17	Primary malignant ovarian carcinoid; management and outcomes. Gynecologic Oncology, 2020, 157, 101-105.	1.4	4
18	Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling. Journal of Clinical Oncology, 2020, 38, 1389-1397.	1.6	48

#	Article	IF	CITATIONS
19	Cervical carcinoma in the setting of uterovaginal prolapse: comparing standard versus tailored management. Ecancermedicalscience, 2020, 14, 1043.	1.1	4
20	Clinicopathologic features of endometrial cancer with mismatch repair deficiency. Ecancermedicalscience, 2020, 14, 1061.	1.1	10
21	Evaluating progression-free survival in black and white women with triple-negative breast cancer in pooled clinical trials from a synthetic control database (SCD) and real-world electronic medical records (EMR) Journal of Clinical Oncology, 2020, 38, e13102-e13102.	1.6	0
22	ls hysterectomy necessary for the treatment of preinvasive stratified mucin producing intraepithelial lesions of the cervix?. International Journal of Gynecological Cancer, 2020, 30, 1298-1302.	2.5	4
23	Outcomes among women with brain metastases from gynecologic (gyn) malignancies Journal of Clinical Oncology, 2020, 38, e18034-e18034.	1.6	0
24	Minimally Invasive Staging of Apparent Stage I Malignant Ovarian Germ Cell Tumors: Prevalence and Outcomes. Journal of Minimally Invasive Gynecology, 2019, 26, 471-476.	0.6	4
25	Incidence of isolated para-aortic lymph node metastasis in early stage endometrial cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 242, 43-46.	1.1	7
26	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
27	International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. American Journal of Obstetrics and Gynecology, 2019, 221, 237.e1-237.e11.	1.3	93
28	Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma. Gynecologic Oncology, 2019, 154, 401-404.	1.4	5
29	Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, andMLH1methylation improved the diagnosis of Lynch syndrome across the population?. Cancer, 2019, 125, 3172-3183.	4.1	59
30	Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 2, 100012.	1.1	9
31	Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. Gynecologic Oncology Reports, 2019, 28, 54-57.	0.6	6
32	Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors. International Journal of Gynecological Cancer, 2019, 29, 554-559.	2.5	7
33	Role of adjuvant chemotherapy in the management of non-granulosa cell ovarian sex cord-stromal tumors. Journal of Gynecologic Oncology, 2019, 30, e19.	2.2	9
34	Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center. Cancer, 2019, 125, 690-697.	4.1	14
35	The effect of the Affordable Care Act on genetic testing patterns and outcomes for inheritable cancer syndromes: A single institution experience Journal of Clinical Oncology, 2019, 37, e13157-e13157.	1.6	1
36	Lynch-like syndrome in endometrial cancer: Features of a growing population Journal of Clinical Oncology, 2019, 37, 5585-5585.	1.6	1

#	Article	IF	CITATIONS
37	Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?. Journal of Clinical Oncology, 2019, 37, e17119-e17119.	1.6	0
38	Small Cell Carcinoma of the Ovary: A Rare Tumor With a Poor Prognosis. International Journal of Gynecological Cancer, 2018, 28, 932-938.	2.5	18
39	IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature, 2018, 562, 423-428.	27.8	252
40	Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population. Maturitas, 2017, 96, 45-50.	2.4	15
41	Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma. Gynecologic Oncology, 2017, 144, 414-419.	1.4	38
42	Rhabdomyosarcoma of the lower female genital tract: an analysis of 144 cases. Archives of Gynecology and Obstetrics, 2017, 296, 327-334.	1.7	50
43	Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors. Gynecologic Oncology, 2017, 145, 243-247.	1.4	27
44	Primary lymphoma of the female genital tract: An analysis of 697 cases. Gynecologic Oncology, 2017, 145, 305-309.	1.4	67
45	Fertility-preserving surgery for advanced stage ovarian germ cell tumors. Gynecologic Oncology, 2017, 147, 493-496.	1.4	27
46	Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?. Gynecologic Oncology, 2017, 147, 81-84.	1.4	22
47	Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecologic Oncology, 2017, 147, 296-301.	1.4	30
48	Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?. Journal of Gynecologic Oncology, 2017, 28, e71.	2.2	27
49	Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma. Journal of Gynecologic Oncology, 2017, 28, e46.	2.2	36
50	Underutilization of multigene panels among Ashkenazi Jewish patients Journal of Clinical Oncology, 2017, 35, 1533-1533.	1.6	0
51	Patterns of genetic screening for hereditary cancer syndromes: Effect of Supreme Court's ruling invalidating single gene patent rights Journal of Clinical Oncology, 2017, 35, 1580-1580.	1.6	0
52	Does race play a role in genetic screening for hereditary cancer syndromes?. Journal of Clinical Oncology, 2017, 35, 1578-1578.	1.6	0
53	Disparities in Gynecological Malignancies. Frontiers in Oncology, 2016, 6, 36.	2.8	57
54	Cytomorphology of Gastricâ€Type Cervical Adenocarcinoma on a ThinPrep Pap Test: Report of a p16â€Positive Tumor Case. Diagnostic Cytopathology, 2016, 44, 710-713.	1.0	6

#	Article	IF	CITATIONS
55	Malignant Brenner tumors of the ovary; a population-based analysis. Gynecologic Oncology, 2016, 142, 44-49.	1.4	45
56	Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study. Gynecologic Oncology, 2016, 141, 128-133.	1.4	20
57	Detection of in situ and invasive endocervical adenocarcinoma on ThinPrep Pap Test: Morphologic analysis of false negative cases. CytoJournal, 2016, 13, 28.	1.7	11
58	Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass. International Journal of Cancer, 2015, 137, 2879-2884.	5.1	8
59	ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell, 2015, 161, 1527-1538.	28.9	639
60	Detection of In Situ and Invasive Endocervical Adenocarcinoma on ThinPrep Pap Test: Cytological-Histological Correlation in 78 Patients. American Journal of Clinical Pathology, 2015, 144, A079-A079.	0.7	0
61	Sclerosing mesenteritis mimics gynecologic malignancy. Gynecologic Oncology Reports, 2015, 12, 49-51.	0.6	1
62	Does speculum lubricant affect liquidâ€based Papanicolaou test adequacy?. Cancer Cytopathology, 2014, 122, 221-226.	2.4	12
63	Knowledge of Lynch syndrome among obstetrician/gynecologists and general surgeons. International Journal of Gynecology and Obstetrics, 2014, 126, 161-164.	2.3	11
64	Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecologic Oncology, 2014, 133, 353-361.	1.4	171
65	Cotyledonoid dissecting leiomyoma. International Journal of Gynecology and Obstetrics, 2014, 125, 284-284.	2.3	2
66	Prognostic Significance of Mucinous Differentiation of Endometrioid Adenocarcinoma of the Endometrium. Cancer Investigation, 2013, 31, 500-504.	1.3	11
67	Lynch Syndrome: Awareness among Medical Students at a United States Medical School. Current Women's Health Reviews, 2012, 8, 242-247.	0.2	6
68	Mucinous histology is a risk factor for nodal metastases in endometrial cancer. Gynecologic Oncology, 2012, 125, 541-545.	1.4	31
69	Embryonal Rhabdomyosarcoma of the Cervix and Appendiceal Carcinoid Tumor. Obstetrics and Gynecology, 2011, 117, 482-484.	2.4	10
70	Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. American Journal of Obstetrics and Gynecology, 2011, 205, 358.e1-358.e6.	1.3	97
71	Postoperative Bowel Herniation in a 5-mm Nonbladed Trocar Site. Journal of the Society of Laparoendoscopic Surgeons, 2010, 14, 289-291.	1.1	16
72	Cervical Cancer Screening. Surgical Oncology Clinics of North America, 2005, 14, 777-797.	1.5	11

#	Article	IF	CITATIONS
73	Complications after Cone Biopsy in Women Infected with the Human Immunodeficiency Virus. Obstetrics and Gynecology, 2002, 99, 39S-40S.	2.4	0
74	Patient and Caregiver Characteristics Associated with Refused Trial of Labor after Cesarean Delivery. Obstetrics and Gynecology, 2002, 99, 52S.	2.4	0
75	E-Cadherin Expression in Endometrioid, Papillary Serous, and Clear Cell Carcinoma of the Endometrium. Obstetrics and Gynecology, 2002, 100, 1290-1295.	2.4	3
76	Magnetic Resonance Imaging in the Preoperative Determination of Tumor Resectability in Previously Irradiated Groin Tumor. Gynecologic and Obstetric Investigation, 2001, 51, 143-144.	1.6	0
77	Microcystic Adnexal Carcinoma of the Vulva. Gynecologic Oncology, 2001, 82, 571-574.	1.4	30
78	Rapid Progression of Primary Vaginal Squamous Cell Carcinoma in a Young HIV-Infected Woman. Gynecologic Oncology, 2000, 78, 380-382.	1.4	20
79	Computed Tomography Guided Core Needle Biopsy Diagnosis of Pelvic Actinomycosis. Gynecologic Oncology, 2000, 79, 318-323.	1.4	50
80	Angiogenesis in Early-Invasive and Low-Malignant-Potential Epithelial Ovarian Carcinoma. Obstetrics and Gynecology, 2000, 95, 548-552.	2.4	1
81	Pleomorphic Rhabdomyosarcoma of the Uterus in a Postmenopausal Woman with Elevated Serum CA125. Gynecologic Oncology, 1999, 74, 499-501.	1.4	22
82	The Efficacy of Cervical Conization in the Treatment of Cervical Intraepithelial Neoplasia in HIV-Positive Women. Gynecologic Oncology, 1999, 74, 428-431.	1.4	45
83	The Significance of ASCUS Cytology in HIV-Positive Women. Gynecologic Oncology, 1999, 75, 118-121.	1.4	25
84	Malignant Transformation of an Ovarian Mature Cystic Teratoma Presenting as a Rectal Mass. Gynecologic Oncology, 1999, 75, 499-503.	1.4	25
85	RAPID PROGRESSION TO INVASIVE CERVIX CANCER IN A WOMAN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS. Obstetrics and Gynecology, 1998, 91, 848-850.	2.4	3